Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Intellia Therapeutics (NTLA) to $45 from $50 and keeps an Overweight rating on the shares. The firm notes continued strong momentum for enrollment in Intellia’s phase 3 studies, boding well for commercial adoption. Wells also thinks the expansion of MAGNITUDE makes sense as it may support differentiated label and use, and note lack of impact to timeline.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
- Intellia Therapeutics Reports Q2 2025 Progress and Financials
- Intellia Therapeutics: Strategic Advancements and Promising Clinical Trials Justify Buy Rating
- Intellia Therapeutics: Strategic Advancements and Promising Clinical Developments Drive Buy Rating
- Intellia Therapeutics price target lowered to $21 from $25 at RBC Capital